TY - JOUR
T1 - Alzheimer's disease normative cerebrospinal fluid biomarkers validated in pet amyloid-β characterized subjects from the Australian imaging, biomarkers and lifestyle (AIBL) study
AU - Li, Q.X.
AU - Villemagne, V.L.
AU - Doecke, J.D.
AU - Rembach, A.
AU - Sarros, S.
AU - Varghese, S.
AU - Mcglade, A.
AU - Laughton, K.M.
AU - Pertile, K.K.
AU - Fowler, C.J.
AU - Rumble, R.L.
AU - Trounson, B.O.
AU - Taddei, K.
AU - Rainey-Smith, S.R.
AU - Laws, S.M.
AU - Robertson, J.S.
AU - Evered, L.A.
AU - Silbert, B.
AU - Ellis, K.A.
AU - Rowe, C.C.
AU - Macaulay, S.L.
AU - Darby, D.
AU - Martins, Ralph
AU - Ames, D.
AU - Masters, C.L.
AU - Collins, S.
PY - 2015/8/28
Y1 - 2015/8/28
N2 - Background: The cerebrospinal fluid (CSF) amyloid-β (Aβ)1-42, total-tau (T-tau), and phosphorylated-tau (P-tau181P) profile has been established as a valuable biomarker for Alzheimer's disease (AD). Objective: The current study aimed to determine CSF biomarker cut-points using positron emission tomography (PET) Aβ imaging screened subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, as well as correlate CSF analyte cut-points across a range of PET Aβ amyloid ligands. Methods: Aβ pathology was determined by PET imaging, utilizing 11C-Pittsburgh Compound B, 18F-flutemetamol, or 18Fflorbetapir, in 157 AIBL participants who also underwent CSF collection. Using anINNOTEST assay, cut-points were established (Aβ 1-42 >544 ng/L, T-tau
AB - Background: The cerebrospinal fluid (CSF) amyloid-β (Aβ)1-42, total-tau (T-tau), and phosphorylated-tau (P-tau181P) profile has been established as a valuable biomarker for Alzheimer's disease (AD). Objective: The current study aimed to determine CSF biomarker cut-points using positron emission tomography (PET) Aβ imaging screened subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, as well as correlate CSF analyte cut-points across a range of PET Aβ amyloid ligands. Methods: Aβ pathology was determined by PET imaging, utilizing 11C-Pittsburgh Compound B, 18F-flutemetamol, or 18Fflorbetapir, in 157 AIBL participants who also underwent CSF collection. Using anINNOTEST assay, cut-points were established (Aβ 1-42 >544 ng/L, T-tau
U2 - 10.3233/JAD-150247
DO - 10.3233/JAD-150247
M3 - Article
VL - 48
SP - 175
EP - 187
JO - Journal of Alzheimer's Disease
JF - Journal of Alzheimer's Disease
SN - 1387-2877
IS - 1
ER -